BCL-2 Inhibitor [EPC]

62878 reported adverse events

Drugs of this class: VENETOCLAX

These side effects are most commonly reported by patients taking drugs of the BCL-2 Inhibitor [EPC] class:

# Side effect Count
0 DEATH 10347
1 OFF LABEL USE 7028
2 NEUTROPENIA 3635
3 FEBRILE NEUTROPENIA 3178
4 MYELOSUPPRESSION 3045
5 PLATELET COUNT DECREASED 2936
6 PYREXIA 2849
7 PNEUMONIA 2733
8 FATIGUE 2723
9 DIARRHOEA 2438
See all common reactions for BCL-2 Inhibitor [EPC]

Drugs of the BCL-2 Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PLATELET TRANSFUSION 401 0.3113
1 CHRONIC LYMPHOCYTIC LEUKAEMIA RECURRENT 211 0.3027
2 ACUTE MYELOID LEUKAEMIA RECURRENT 615 0.2862
3 MINIMAL RESIDUAL DISEASE 118 0.2443
4 CHRONIC LYMPHOCYTIC LEUKAEMIA 778 0.1638
5 BONE MARROW TRANSPLANT 284 0.1496
6 MANTLE CELL LYMPHOMA 206 0.1353
7 TUMOUR LYSIS SYNDROME 1180 0.1340
8 BLAST CELL COUNT INCREASED 137 0.1307
9 ACUTE MYELOID LEUKAEMIA 1935 0.1240
See all enriched reactions for BCL-2 Inhibitor [EPC]